A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...

UCL-led trial shows adding niraparib to standard therapy reduces tumour growth risk in men with advanced prostate cancer by ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

A drug used to treat type 2 diabetes may also be effective in slowing the progression of prostate cancer. This is shown by an international study in which researchers at Umeå University, Sweden, have ...

A drug used to treat type 2 diabetes may also be used to treat prostate cancer. The corresponding study was published in Molecular Cancer. "This is a significant discovery. For the first time, we have ...

A UCLA study shows that a new treatment combining radioactive drug with radiation therapy could help delay hormone therapy ...

TUPELO — Some avid watchers of football broadcasts have no doubt become aware of a drug called Pluvicto. That’s because commercials touting the relatively new drug were meant to target a large ...

Diabetes medications known as GLP-1 receptor agonists (GLP-1RAs), widely prescribed for type 2 diabetes and weight loss, have complex and varied effects on cancer risk that depend on cancer type and ...

Studies have shown the popular weight loss drugs known as GLP-1 agonists may be helpful for more than just curbing appetite — and new research is looking at their potential impact on cancer risk.

MILAN, Italy — In patients with prostate cancer and cardiovascular disease, degarelix (Firmagon, Ferring Pharmaceuticals) is associated with fewer serious adverse events and less all-cause death ...

GLP-1 receptor agonists (RAs) were associated with a 17% lower overall cancer risk in adults with obesity or overweight, with particularly reduced risks for endometrial, ovarian, and meningioma ...